Pranav Garimella

Awesome infographic on genetic testing in ADPKD by Neera Dahl, @pranavgarimella.bsky.social and Fouad Chebib www.kidneynews.org/view/journal...

28.07.2025 19:29 — 👍 56    🔁 11    💬 2    📌 0

Thank you to @pranavgarimella.bsky.social and @kidneyfund.bsky.social for the interview!

04.09.2025 18:42 — 👍 2    🔁 1    💬 0    📌 0

Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study

bit.ly/AJKDAscher25

@pranavgarimella.bsky.social

02.05.2025 16:07 — 👍 6    🔁 3    💬 0    📌 0

Diagram showing all uric acid lowering therapies MoA Figure 1 Title: Summary of common urate-lowering therapies and their mechanisms of action, Legend: Allopurinol and febuxostat are xanthine oxidase inhibitors, reducing the rate of uric acid production. Rasburicase and pegloticase are recombinant uricases that promote conversion of uric acid to allantoin, which is readily excreted in the urine. Probenecid is a nonspecific inhibitor of URAT1 to a much greater extent than OAT1, OAT3, and GLUT9 with a net effect of uricosuria. Dotinurad is a specific URAT1 inhibitor, inhibiting proximal tubular reabsorption of uric acid thereby promoting uricosuria. UA: uric acid; GLUT: glucose cotransporter; NPT: sodium-dependent phosphate transport protein; ABCG2: ATP-binding cassette subfamily G; OAT: organic anion transporter; URAT: uric acid transporter.

Dotunirab - URAT-1 inhibitor which prevents uric acid reabsorption = uricosuric

Nice commentary from @pranavgarimella.bsky.social & Amy Li in @kireports.bsky.social www.kireports.org/article/S246...

Drugs mostly only available in Japan Department

#NephSky #RheumSky

05.05.2025 12:32 — 👍 15    🔁 4    💬 1    📌 0

A Combination Approach to Improving Prognostication in... : Clinical Journal of the American Society of Nephrology An abstract is unavailable.

🚨Should we consider a new approach to enhance prognostication in PKD?

See our editorial on CJASN ⭐️👇
@asnkidney.bsky.social
#endPKD @pranavgarimella.bsky.social @ucsdhealthsci.bsky.social

journals.lww.com/cjasn/Fullte...

12.03.2025 06:14 — 👍 2    🔁 2    💬 0    📌 0

Happening now, Drs @hswapnil.medsky.social and @jordybc.bsky.social discuss resistant hypertension during day 3 of the @kidneyfund.bsky.social #KidneyActionWeek

Fantastic discussion!

05.03.2025 16:25 — 👍 5    🔁 3    💬 0    📌 0

Estimating global article processing charges paid to six publishers for open access between 2019 and 2023 This study presents estimates of the global expenditure on article processing charges (APCs) paid to six publishers for open access between 2019 and 2023. APCs are fees charged for publishing in some ...

Fascinating read on the ever frustrating topic of publication fees: this paper estimates that between 2019 and 2023 researchers and institutions paid a whopping USD $8.968 billion for their findings to be freely accessible and that costs tripled during that time 💰

arxiv.org/abs/2407.16551

05.03.2025 06:50 — 👍 3    🔁 4    💬 0    📌 0

Dr. Pranav Garimella, Chief Medical Officer of AKF & Dr. Vasishta Tatapudi | Xenotransplantation Dr. Pranav Garimella, Chief Medical Officer of the American Kidney Fund, sits down with Dr. Vasishta Tatapudi, a transplant nephrologist at NYU Langone, for a deep dive into the FDA’s recent approval of xenotransplantation clinical trials and what it means for the kidney community.

@pranavgarimella.bsky.social, Chief Medical Officer of the American Kidney Fund, sat down with Dr. Vasishta Tatapudi of NYU Langone Health for a deep dive into xenotransplantation and what it means for the kidney community. Watch the full interview: bit.ly/4khsp23

28.02.2025 17:25 — 👍 3    🔁 1    💬 0    📌 0

Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

AKF Chief Medical Officer @pranavgarimella.bsky.social sat down with @pharmacytimes.bsky.social to discuss the recent FDA approval of semaglutide to reduce kidney disease & cardiovascular death risks in adults with type 2 diabetes & chronic kidney disease. Watch the interview: bit.ly/41sSynb

21.02.2025 16:12 — 👍 3    🔁 2    💬 0    📌 0

This is what I am worried about too, Graham. The large volume of patients in CA and especially here as you know who rely on emergency Medi-Cal for dialysis is enormous

21.02.2025 15:16 — 👍 2    🔁 2    💬 1    📌 0

Hey #NephSky anyone ever heard of orthotopic kidney transplant (nephrectomy & transplant combined)? Have a patient with a good match living donor but poor femoral vessel targets due to calcium. Been turned down twice for kidney transplant surgery due to calcified vessels.

04.02.2025 17:16 — 👍 7    🔁 4    💬 1    📌 0

@gokidgo.bsky.social @ecorneclegall.bsky.social

21.01.2025 15:31 — 👍 1    🔁 0    💬 0    📌 0

@edgarvlermamd.bsky.social

21.01.2025 15:29 — 👍 1    🔁 0    💬 1    📌 0

Finally, the KDIGO 2025 #ADPKD Guidelines are out.
Whats in it?

✅ Genetic screening for persons at risk
✅ Best approach to managing cyst infection
✅ Considerations for treatment with tolvaptan
✅ ADPKD and mental health

All this and much more! www.kidney-international.org/article/S008...

21.01.2025 15:29 — 👍 5    🔁 4    💬 1    📌 0

I am happy to announce my appointment as @kidneyfund.bsky.social first Chief Medical Officer! I look forward to lending my clinical expertise to help AKF better serve the 1 in 7 Americans living with kidney disease & joining an organization that fights kidney disease on all fronts.

08.01.2025 16:56 — 👍 13    🔁 3    💬 3    📌 0

Hello Blue Sky

05.12.2024 14:41 — 👍 9    🔁 1    💬 0    📌 0